Press releases

Results Of Firm Placing And Placing And Open Offer

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL
 
THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF ANY OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY NEW ORDINARY SHARES, NOR SHALL IT (OR ANY PART OF IT), OR THE FACT OF ITS DISTRIBUTION, FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH OR ACT AS ANY INDUCEMENT TO ENTER INTO, ANY CONTRACT OR COMMITMENT WHATSOEVER WITH RESPECT TO THE PROPOSED FIRM PLACING AND PLACING AND OPEN OFFER OR OTHERWISE. THIS ANNOUNCEMENT IS NOT A PROSPECTUS AND INVESTORS SHOULD NOT SUBSCRIBE FOR OR PURCHASE ANY NEW ORDINARY SHARES REFERRED TO IN THIS ANNOUNCEMENT EXCEPT SOLELY ON THE BASIS OF INFORMATION IN THE PROSPECTUS THAT WAS PUBLISHED ON 13 DECEMBER 2010. COPIES OF THE PROSPECTUS ARE AVAILABLE FROM OXFORD BIOMEDICA’S HEAD OFFICE AT MEDAWAR CENTRE, ROBERT ROBINSON AVENUE, THE OXFORD SCIENCE PARK, OXFORD, OX4 4GA.
 
OXFORD BIOMEDICA PLC
 
RESULTS OF FIRM PLACING AND PLACING AND OPEN OFFER

 
On 13 December 2010, the Board of Oxford BioMedica plc (the “Company” or “Oxford BioMedica”) announced details of a proposed share issue to raise gross proceeds of £20 million (£18.4 million net of expenses) by way of a firm placing of 278,916,543 new ordinary shares of 1 pence each (the “New Ordinary Shares”) (the “Firm Placing”) and a placing and open offer of up to 121,083,457 New Ordinary Shares (the “Placing and Open Offer)” at a price of 5 pence per New Ordinary Share.

Defined terms used in this announcement shall have the same meaning as those terms defined and used in the prospectus of the Company dated 13 December 2010.
 
The Open Offer closed for acceptances at 11.00 a.m. on 6 January 2011. At that time the Company had received valid acceptances in respect of 115,756,980 Open Offer Shares from Qualifying Shareholders. This represents approximately 95.6 per cent. of the Open Offer Shares offered. All eligible applications received from Qualifying Shareholders will be allocated their pre-emption entitlements and all eligible applications under the Excess Application Facility will be allocated their Open Offer Shares as applied for.

The Firm Placing and Placing and Open Offer remain conditional, amongst other things, upon the passing of the Resolutions at the General Meeting, to be held at 10.00 a.m. on 7 January 2011 and Admission occurring no later than 8.00 a.m. on 10 January 2011 or such later time or date as the parties to the Placing Agreement may determine.
 
Application has been made to the UK Listing Authority for the New Ordinary Shares to be admitted to the premium segment of the Official List and to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on the London Stock Exchange's main market for listed securities. It is expected that Admission will become effective on 10 January 2011 and that dealings in the New Ordinary Shares will commence at 8.00 a.m. on 10 January 2011. Thereafter, Oxford BioMedica will have a total of 944,875,557 Ordinary Shares in issue.
 
The New Ordinary Shares, when issued and fully paid will rank equally in all respects with the Existing Ordinary Shares.
 
This announcement should be read in conjunction with the full text of the Prospectus. A copy of the Prospectus is available at the UKLA's National Storage Mechanism and will be available for inspection at www.hemscott.com. In addition, the Prospectus is available to view on the Company's website (www.oxfordbiomedica.co.uk). Copies of the Prospectus are also available from the offices of Oxford BioMedica plc, Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA.

- Ends -

Notes to editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications – Media Enquiries

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton

Tel: +44 (0)20 3709 5700

 

Jefferies (Corporate Broker) 

Gil Bar-Nahum/Simon Hardy/Lee Morton/Max Jones/Nicholas Moore

Tel: +44 (0)20 7029 8000